Expression of p53 isoforms in squamous cell carcinoma of the head and neck.
暂无分享,去创建一个
J. Bourdon | B. Sjöström | P. Coates | K. Nylander | Philip J Coates | Jean-Christophe Bourdon | Linda Boldrup | Björn Sjöström | Karin Nylander | L. Boldrup
[1] B. Sjöström,et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. , 2004, International journal of oncology.
[2] A Estreicher,et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. , 1996, Oncogene.
[3] P. Hainaut,et al. ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53 , 2002, Oncogene.
[4] Chikashi Ishioka,et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.
[5] M. Gatei,et al. Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53 , 2001, Oncogene.
[6] David P Lane,et al. p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.
[7] B. Sjöström,et al. Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers. , 2005, International journal of oncology.
[8] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[9] A. Yang,et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.
[10] P. Hall,et al. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[11] D. Lane,et al. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress , 2006, Cell Death and Differentiation.
[12] A. Yang,et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.
[13] M. Kulesz-Martin,et al. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. , 1992, Nucleic acids research.
[14] F. McKeon,et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. , 2000, Science.
[15] V. Chow,et al. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. , 1993, Cancer letters.
[16] G. Melino,et al. Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.
[17] Wolf,et al. Immunologically distinct p53 molecules generated by alternative splicing , 1986, Molecular and cellular biology.
[18] D. Lane,et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.
[19] W. Deppert,et al. A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.
[20] J. Kovarik,et al. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. , 1995, Oncogene.
[21] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[22] D. Lane,et al. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. , 1995, Journal of molecular biology.
[23] V. Rotter,et al. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule , 1985, Molecular and cellular biology.
[24] Yili Yin,et al. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products , 2002, Nature Cell Biology.
[25] G. Matlashewski,et al. Regulation of Human p53 Activity and Cell Localization by Alternative Splicing , 2004, Molecular and Cellular Biology.